Overview

Dexamethasone (0.4mg) Ophthalmic Insert.

Status:
Not yet recruiting

Trial end date:
2022-10-01

Target enrollment:

Participant gender:

Summary

To assess the safety and effectiveness of treatment with an intracanalicular dexamethasone (0.4mg) insert in the operating room following cataract surgery/intraocular lens implant (IOL) with or without iStent/Hydrus/Goniotomy when placed in the lower punctum compared to the upper punctum.

Phase:

Phase 4

Details

Lead Sponsor:

Iworks Laser and Vision Center

Collaborator:

Ocular Therapeutix, Inc.

Treatments:

BB 1101
Dexamethasone
Dexamethasone acetate